Peter P. Pfreundschuh - Jul 12, 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role: CFO and Treasurer
Signature: /s/ John LaRocca, Attorney-in-Fact
Stock symbol: YMAB
Transactions as of: Jul 12, 2024
Transactions value $: $0
Form type: 4
Date filed: 7/12/2024, 05:29 PM
Previous filing: Jul 8, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	YMAB	Common Stock	Award	$0	+46K		$0.00	46K	Jul 12, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	YMAB	Employee Stock Option (right to buy)	Award	$0	+170K		$0.00	170K	Jul 12, 2024	Common Stock	170K	$12.47	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSU. The RSUs vest by 1/3 on each of July 12, 2025, July 12, 2026 and July 12, 2027, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2	Stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan.
F3	The stock options shall vest and become exercisable as to 25% of the shares subject to the option on July 12, 2025, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.